Recent

% | $
Quotes you view appear here for quick access.

STAAR Surgical Company Message Board

  • jusdoit91 jusdoit91 Jan 7, 2004 12:35 PM Flag

    I invest and also trade

    been watching closely and it appears that this puppy has a good shot to close over the high of the day at 9.73

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the CC:
      Bottom line (mine) -- Staar on track, minor blip, bad news only temporarily painful...Bailey answered plainly and well.

      Dr. Tom Paul, formerly of CibaVision, is now Director of R&D, as long-planned addition, not in response to FDA. Strong background, will lead root-cause analyses responding to FDA.

      Staar is recalling on its own (not per FDA) 6K cartridges from specified lots, cost $15K; already updated release standards; may have spot delivery shortages.

      Staar received FDA letter 29 Dec, response w/i 15 business days hence. Visiting FDA Compliance Dept in WashDC next week. Anticipate completing QC changes and requesting re-inspection/audit such that it will be completed not affecting FDA approval of ICL with original 6-month window (i.e. before 1 April!).

      Staar considered initial FDA letter and Staar response as "work in progress" and not "material information", whereas the FDA warning letter was "material info" impacting investors.

      Jason Bedford/Adams Harkness, Ryan Rausch/SuntrustRH, Kate Sarandon/Pacific Growth Equities, Joanne Lynch/Harris Nesbitt, John Calcagini/CIBC, Marvin Spurling/ING, John Nicholson/San Leaf Partners? were analysts asking questions in the Q&A.

 
STAA
7.43-0.080(-1.07%)Mar 31 4:00 PMEDT